Diffuse and disseminated cutaneous leishmaniasis: clinical cases experienced in Ecuador and a brief review
© Hashiguchi et al 2016
Received: 26 October 2015
Accepted: 28 October 2015
Published: 14 March 2016
In Ecuador, cutaneous leishmaniasis (CL) is prevalent countrywide, but only one case of diffuse-CL and two cases of disseminated-CL were experienced during our research activities more than 30 years from 1982 to date. These three patients suffered from multiple lesions distributed at a wide range of the body surface, revealing difficulty to clinically differentiate each other.
There is a considerable confusion of the use and/or differentiation of the terminologies (terms) between the two disease forms, diffuse-CL and disseminated-CL. One of the aims of the present study is to clarify the difference between the two disease forms, mainly based on the cases experienced in Ecuador.
The disseminated-CL case newly reported here was clinically very similar to the diffuse-CL case, but the former showed the following marked differences from the latter: (1) the organisms isolated were identified as the parasites of Leishmania (Viannia) guyanensis/panamensis, which are also known as the causative agents of disseminated-CL in different endemic countries of the New World; (2) the patient was sensitive against antimonials; and (3) mucosal involvement was observed, which is never observed in diffuse-CL.
In the text, three clinical cases, one diffuse-CL and two disseminated-CL, were presented. Furthermore, a bibliographic comparison of the features between the two disease forms was made, and a brief comment was also given.
KeywordsCutaneous leishmaniasis Diffuse Disseminated Differentiation Ecuador Old and New Worlds
Leishmaniases are one of the vector-borne diseases, caused by obligate intra-macrophage protozoan parasites of the genus Leishmania, with subgenera Leishmania and Viannia. The disease is transmitted by the bite of infected female phlebotomine sand flies of the genera Phlebotomus and Lutzomyia in the Old and New Worlds, respectively. In humans, about 20 Leishmania species are responsible for a wide spectrum of clinical manifestations, ranging from localized cutaneous leishmaniasis (CL) to those producing diffuse-CL and disseminated-CL, mucocutaneous (MCL), and visceral (VL) forms known as kala-azar. These different types of the disease are endemic in many tropical and subtropical regions and responsible for increasing health problems in large parts of the world [1, 2].
The diffuse-CL case was reported for the first time by Convit and Lapenta from Venezuela in the New World and then by Destombes et al. from Ethiopia in the Old World [3, 4]. The former authors reported one case as an atypical clinical form in Spanish version entitled “Sobre un caso de leishmaniasis tegmentaria de forma diseminada” (one case of disseminated form of tegumentary leishmaniasis) in a Venezuelan medical journal. Later, the latter authors reported a similar case from Ethiopia in French version entitled “Leishmaniose cutanee nodulaire disseminee en Ethiopie” (disseminated cutaneous nodular leishmaniasis in Ethiopia). The authors of the two articles used the same terminology “disseminate” against diffuse-CL forms in the title. After these reports, some workers like to use “disseminate” against diffuse-CL and others used “diffuse” against the same disease form (diffuse-CL). On the other hand, disseminated-CL cases in the New World were reported for the first time by Costa et al. and then by Carvalho et al. and Turetz et al. from Brazil [5–7]. The disseminated-CL is mainly found in the New World.
Thus, for many years, diffuse-CL and disseminated-CL remain clinical forms of the well-classified skin manifestations of the disease. Still, however, there is a considerable confusion of the utilization or differentiation of the terminology between the two disease forms. We therefore tried to emphasize the correct and precise differentiation of the two clinical forms. In the text, three clinical cases, one diffuse-CL and two disseminated-CL, were presented. Furthermore, a brief review was given, performing a bibliographic comparison between the two disease forms. Informed consent was obtained from the subjects who participated.
Patient’s origin and identification of Leishmania species
Clinical samples from patients
Clinical samples from diffuse-CL (Muisne) and disseminated-CL (Cumanda) were taken by scraping the margin of active lesions of the patients, spotted onto a FTA classic card (Whatman, Newton Center, MA), and stored at room temperature. Disks 2 mm in diameter were punched out from each filter paper and washed three times with FTA purification reagent (Whatman) and once with Tris-EDTA buffer. The disks were air-dried and directly subjected to PCR amplification. Nested PCR was performed to amplify the Leishmania cytochrome b (cyt b) gene from a patient specimen collected on the FTA cards. Primers used for the nested PCR were L.cyt-AS (5′-GCGGAGAGRARGAAAAGGC-3′) and L.cyt-AR (5′-CCACTCATAAATA TACTATA-3′) for the first PCR and L.cyt-S and L.cyt-R for the second PCR [8, 9].
Montenegro (Leishmanin) skin test and recombinant kinesin-like antigen (rK39) kit test
To see the cellular immune response of the subjects examined, intradermal skin test antigen derived from Leishmania (Viannia) panamensis promastigotes was applied to the subjects; more than 5 mm in diameter of the induration was considered as positive . Besides, recombinant kinesin-like K39 kit test (rK39 antigen of L. (Leishmania) chagasi produced by InBios International (Kalazar Detect™ Rapid Test kit, Seattle, WA, USA )) was applied to the sera of the subjects, in order to see humoral immune response.
Cytochrome b (cyt b) gene sequence was performed with CLUSTAL W software  and examined using the program MEGA (Molecular Evolutionary Genetics Analysis) version 5.1 . Phylogenetic trees were constructed by the neighbor-joining method with the distance algorithms available in the MEGA package. Bootstrap values were determined with 1000 replicates of the data sets. The database for phylogenetic analyses consisted of cyt b gene sequences from GenBanks of 12 Leishmania species.
Diffuse and disseminated cutaneous leishmaniasis in Ecuador
A case of diffuse cutaneous leishmaniasis (diffuse-CL)
Histological findings of the specimen taken from nodules on the thigh showed hyperkeratosis and mild acanthosis of the dermis. There was dense cellular infiltration in the dermis. Proliferations of blood vessels were also visible. In the foamy cells, innumerable Leishmania amastigotes were observed. No epithelioid cell granuloma was observed as seen in leprosy. No acid-fast bacilli were observed in the dermis. The patient was treated with meglumine antimoniate (Glucantime®) at a dose of 10 mg/kg/day and sodium stibogluconate (Pentostam®) at a dose of 20 mg/kg/day for 28 days with each drug; partial resolution of skin lesion was observed but relapsed soon after discontinuation of the treatment. In these treatments, the density of parasite on smear specimens was significantly reduced immediately after the beginning of each treatment but never disappeared completely. Thus, relapses were followed by 5- or 6-month intervals after each of the slight clinical improvements. Therefore, the patient had to receive repeatedly the intramuscular injection of Glucantime® after each relapse. Following this antimonial treatment, the patient received also pentamidine (3–4 mg/kg intramuscularly once or twice for a week) but had to be discontinued because of severe adverse reactions such as hypotension, gastrointestinal symptoms, and syncope, without revealing a marked clinical and parasitological healing. Subsequently, the patient was treated with oral itraconazole (200 mg/day for 3 months), mefloquine (4.2 mg/kg/day for 6 days, repeated with a 3-week interval), and artesunate (6.7 mg/kg/day for 3 days, repeated with a 2-week interval), but compete healing was not obtained by any of these drugs. These mixed and alternative treatments were performed one after another because of the lack of any effective drugs for this diffuse-CL patient. The patient was also treated with oral miltefosine [13, 14]. The drug (Impavido®) was started at a dose of 2.5 mg/kg/day and continued for 5 months. However, 2 months after discontinuing miltefosine, small papular lesions appeared and the slit-skin smears and aspirates of lesions had become positive for Leishmania parasites. Miltefosine was re-started at the same dose, but no clinical or parasitological response was observed even after 2 months of re-treatment, and skin lesions continued to grow and spread over the entire body . No specific and efficient drug is available for the diffuse-CL in the world at the moment.
Two cases of disseminated cutaneous leishmaniasis (disseminated-CL)
The first case of disseminated-CL
We diagnosed the first case of disseminated-CL in Ecuador and named it as “generalized CL” . The patient was a 40-year-old female, as of the time of examination (August 1979). The patient came from a small village, Balao Chico, Guayas province, a mountainous area located at 200 m a.s.l. (Fig. 1 (2)). At the early phase of the disease, the lesion appeared on the lumbar region, and then papular lesions were seen, which became pustulous vesicles at the right lumber region and disseminated all over the body, demonstrating 308 generalized lesions counted. The patient revealed a marked right lumbar pain, and some of the lesions in the body surface suspecting herpes zoster were observed. The patient was admitted for 16 days in a private hospital and then was taken to a national hospital “Hospital Luis Vernaza” in Guayaquil city, Ecuador. She was admitted to the hospital under the suspected diagnosis of smallpox, being registered No. 03739 in August 1979, without a precise diagnosis. As there was no improvement of her lesions on the 15th day of admission, she was taken to receive differential diagnosis at the National Institute of Tropical Medicine and Hygiene, Guayaquil city, Ecuador. The presumptive clinical diagnoses were paracoccidioidomycosis, cutaneous leishmaniasis, or staphylococcal infections. Firstly, the case was considered as paracoccidioidomycosis suggesting a generalized cutaneous form of the disease. But either Paracoccidioides braziliensis or Staphylococcus aureus were not observed in the examination of ulcer materials. Laboratory examinations revealed positive for betahemolytic streptococcus and sensitive for erythromycin, cephalexin, amikacin, and ampicillin and stool examination positive for Trichuris trichiura, Ascaris lumbricoides, and Ancylostoma duodenale.
Most of the ulcer was crusty. When lifting the crusts, they were excavated with a purulent fluid because of sever secondary infections. The ulcers had different sizes ranging from 0.5 to 20 mm in diameter. Some lesions had thick, prominent, and adhered crusts that bleed easily when they were separated. Others were small crusty ulcers that left an excavation, and some of them were erythematous and papulous, and confluent plaques were found on the lumbar-dorsal region. Several smear samples from diverse regions of the body surface were taken at random. The samples were positive for the Leishmania amastigote, though the number was scanty in smear specimens. The parasite isolated was identified as L. (V.) panamensis (designated as MHOM/EC/95/NA-03) by ELISA species-specific monoclonal antibodies (serodeme) analysis . No Montenegro skin test and rK39 kit test were performed in the case. The patient responded well to Glucantime® treatment (6.5 mg/kg/day for 12 days). In this case, both metronidazole per os and its ointment were also used as a supplementary treatment; probably, these accelerated the patient’s healing within a short regimen, in spite of a relatively low dose of the drug.
The second case of disseminated-CL
In Ecuador, there are 24 provinces; among them, leishmaniases are prevalent in 21 provinces except Galapagos Is. As the causative agent of the Leishmania spp., there are eight species in total, L. (L.) mexicana, L. (L.) amazonensis, L. (L.) major-like, L. (V.) braziliensis, L. (V.) guyanensis, L. (V.) panamensis, L. (V.) naiffi [9, 17, 18], and the newly found L. (V.) lainsoni (Kato et al., unpublished data). In the country, localized CL is the most frequent clinical feature of the disease, followed by MCL cases mainly seen in the Ecuadorian Amazonian region [17, 18]. Only one diffuse-CL and two disseminated-CL cases in Ecuador were confirmed parasitologically and/or molecular biologically in our research activities from 1982 to date. No VL case was recorded, and its suspected vector species, Lutzomyia longipalpis and L. evansi, are not recorded among 29 species of man-biting sand flies . The present diffuse-CL and disseminated-CL cases are found in the littoral northern (Esmeraldas) and southern (Guayas and Chimborazo) Ecuadorian regions. There will be a possibility of the presence of some unreported cases, especially in the Ecuadorian Amazonian regions, where the disease with diverse clinical manifestations are highly endemic, caused by different Leishmania species mentioned above.
Leishmaniases are caused by the parasites of the genus Leishmania, in which two subgenera Leishmania and Viannia exist. In the Old World, only the subgenus Leishmania is prevailing, while in the New World, both subgenera Leishmania and Viannia are circulating. The subgenus Leishmania parasites are causative agents of diffuse-CL in both the Old and New Worlds. The causative agents of diffuse-CL in the Old World are L. (L.) aethiopica and to a lesser extent L. (L.) major  and L. (L.) amazonensis and L. (L.) mexicana in the New World . In the Old World, the clinical form of diffuse-CL is uncommon other than east Africa, Ethiopia, and Kenya [4, 22], but one each of cases masquerading as leprosy in the context of human immunodeficiency virus (HIV) co-infection was reported from Burkina Faso  and from Senegal . On the other hand, in the New World, species of the subgenus Leishmania, such as L. (L.) mexicana and L. (L.) amazonensis, are responsible for the diffuse-CL in a wide range of South and Central American countries . Among them, L. (L.) mexicana is mainly reported from the Central American countries and from a part of the northern regions of the South America . No diffuse-CL cases caused by species of the subgenus Viannia are reported to date. The diffuse-CL lesions grow and proliferate as nodules and plaques which slowly but relentlessly spread to cover the entire body, with the exception of the scalp, axillae, inguinal fold, palms of the hands, and soles of the feet [25–28]. The diffuse-CL is a rare disease entity, and no more than 1–2 cases are diagnosed in all of Brazil each year .
A bibliographic summary of the differences between diffuse-CL and disseminated-CL cutaneous leishmaniasis in the New and Old Worlds
In the New World
L. (L.) amazonensis
L. (V.) braziliensis group
L. (L.) mexicana
L. (L.) mexicana group
In the Old World
L. (L.) aethiopica
No specific case reports other than HIV co-infection
L. (L.) major
No. of parasites in lesions/smears
Massive/abundant in smear (uncontrolled parasite growth)
Scanty/rare in smear
Leishmanin skin test
Negative/poor (specifically anergic to Leishmania antigen; lack of cell-mediated immunity)
Reaction to TB, PPD, and other antigens
Ulceration of lesions
Coalescence to form plaques
Type of lesions
Nodules, papules, plaques, macules, erythema
Papules, nodules, ulcers (mixture of small lesions)
Response to drug/therapy
Resistant/poor, relapse frequently
Chronic, persist 20 years or more, for a life long
Analogous to lepromatous leprosy
Affected ages and sex
All ages and sexes
Young adults, maleb
No. of lesions
Often innumerable, plaques on body surface
0–300b, 308c, 425d, 745e
Rare, less than 0.1 % of total CL in Venezuelaf
Less than 2 % of CLb
The most marked differences between diffuse-CL and disseminated-CL are the presence of multiple non-ulcerative nodular lesions, a poor T cell response to Leishmania antigen, and a high number of phagocytosed Leishmania parasites within macrophages found in the former but not in the latter . Characteristics of the present diffuse-CL patient corresponded to the previously reported cases, showing non-ulcerative lesions, negative skin test, and innumerable amastigotes in phagocytes. Silveira et al. proposed two pathogenicity extremes, the hypersensitivity pole by MCL and the hyposensitivity pole by anergic/diffuse-CL (ADCL), and they recommended the use of the term “borderline/disseminated-CL (BDCL)” for the disseminated form, caused by parasites of the subgenera Leishmania and Viannia, which might be regarded as intermediate between localized CL and the extreme pathogenicity poles MCL and ADCL . Disseminated-CL is distributed widely in the New World and is characterized by cutaneous lesions, which may be accompanied by mucosal involvement and demonstrate a tendency toward chronicity and relapse as well as resistance to standard treatment regimens; parasites of the subgenus Viannia, L. (V.) braziliensis and L. (V.) guyanensis/panamensis, have been identified as the major etiological agent of this subset of infections [6, 7, 30, 33]. The disseminated-CL is also characterized by the presentation of a large number of acneiform and papular skin lesions, sometimes more than 700, at different anatomical regions such as the body surface, face, limbs, and trunks . Most of the disseminated-CL lesions appear simultaneously with or secondary to one or several ulcerated lesions of localized CL. In an area of northeastern Brazil where L. (V.) braziliensis is endemic, patients with disseminated-CL presented 10–300 lesions that were a mixture of acneiform, papular, nodular, and ulcerated types; 12 (29 %) of 42 patients had mucosal involvement; and the patients with disseminated-CL had lower levels of interferon-γ and tumor necrosis factor-α production, compared with localized-CL patients . An association between disseminated-CL and L. (V.) braziliensis strain polymorphisms was suggested that molecular genotyping may provide markers to identify the strains likely to cause an emerging, hard-to-treat form of disseminated-CL . In the Old World, several cases are literary reported as “disseminated-CL,” but those are co-infection with HIV, caused by L. (L.) major or other unknown species of the subgenus Leishmania . The cases are different from those found in the New World.
In the current study, rK39 rapid kit test revealed positive bands both for the sera of diffuse-CL and disseminated-CL patients. The kit test using L. (L.) chagasi antigen is prepared for the qualitative detection of antibodies to L. (L.) donovani complex in human serum (InBios International, Instructions). However, we applied the test to our cases, expecting the cross-reactions between the Leishmania species, and observed strong positive bands in the cases. Furthermore, in our preliminary study, positive reaction of rK39 kit test against the serum of a MCL patient was also observed, but no positive reaction was found in the sera of localized-CL and mucosal (ML) patients; both are acute and/or relatively mild cases of CL (Hashiguchi et al., unpublished data). Cross-reactions of the rK39 kit test are reported at some extent. For example, positivity in at least one test employing recombinant (rK39) antigen was observed in 24 (45 %) patients with CL from Venezuela and Brazil and 47 (82.4 %) with Plasmodium vivax or P. falciparum from Brazil . On the contrary, using the rK39 kit test, 100 % of the samples from 272 subjects with confirmed CL was negative, confirming the absolute absence of a serological cross-reaction . Based on these results, Molinet et al. proposed the recommendation that the lack of a cross-reaction in CL patients infected by parasites of the same genus highlights the specificity of the rK39 antigen for the diagnosis of VL in areas with the sympatric circulation of L. (V.) braziliensis and L. (L.) infantum in Brazil . Furthermore, Maia et al. mentioned that the rK39 proteins used either in a strip test or in an ELISA and the DAT are the best choices for implementation of rapid, easy, and efficient test for serodiagnosis of VL, performing a systematic review and meta-analysis of the studies published .
In conclusion, the terms, diffuse-CL and disseminated-CL, should be used more correctly, based on the clinical, parasitological, and immunological features of the two forms. Furthermore, diffuse-CL is highly resistant to the drugs, and no specific and efficient medication is available for this disease form in the world. Therefore, the diffuse-CL should be diagnosed precisely at the early phase of the disease, differentiating from disseminated-CL which is sensitive against the available drugs.
We are indebted to Kazue Hashiguchi, Facultad de Medicina, Universidad Catolica de Santiago de Guayaquil, Guayaquil, Equador; Jenny Muzzio, Instituto Nacional de Investigacion de la Salud Publica, Guayaquil; and personnel of the Cumanda Subcentro de Salud, Chimborazo province, Ecuador, for their support during the phase of the manuscript preparation, laboratory examination, and patient management.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans Roy Soc Trop Med Hyg. 2001;95:239–43.View ArticlePubMedGoogle Scholar
- Alvar J, Velez ID, Bern C, Herrero M, et al. WHO Leishmaniasis Control Team, 2012. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2012;7:e35671.View ArticlePubMedPubMed CentralGoogle Scholar
- Convit J, Lapenta M. Sobre un caso de leishmaniasis tegumentaria de forma diseminada. Rev Policlinica Caracas. 1948;17:153–8.Google Scholar
- Destombes P, Poirer A, Serie C. Leishmaniose cutanee nodulaire disseminee en Ethiopie. Arch Inst Pasteur Alger. 1965;43:9–19.Google Scholar
- Costa JM, Marsden PD, Llanos-Cuestas EA, Netto EM, et al. Disseminated cutaneous leishmaniasis in a field clinic in Bahia, Brazil: a report of eight cases. J Trop Med Hyg. 1986;89:319–23.PubMedGoogle Scholar
- Carvalho EM, Barral A, Costa JML, et al. Clinical and immunopathological aspects of disseminated cutaneous leishmaniasis. Act Trop. 1994;56:315–25.View ArticleGoogle Scholar
- Turetz ML, Machado PR, Ko AI, et al. Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J Inf Dis. 2002;186:1829–34.View ArticleGoogle Scholar
- Kato H, Caceres AC, Mimori T, et al. Use of FTA cards for direct sampling of patients’ lesions in the ecological study of cutaneous leishmaniasis. J Clin Microbiol. 2010;48:3661–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Kato H, Calvopina M, Criollo H, et al. First human cases of Leishmania (Viannia) naiffi infection in Ecuador and identification of its suspected vector species. Act Trop. 2013;128:710–3.View ArticleGoogle Scholar
- Furuya M, Nonaka S, Gomez EAL, Hashiguchi Y. Evaluation and characterization of partially purified skin test antigens prepared from Leishmania panamensis promastigotes. Jpn J Trop Med Hyg. 1991;19:209–17.View ArticleGoogle Scholar
- Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22:4673–80.View ArticlePubMedPubMed CentralGoogle Scholar
- Tamura K, Peterson D, Peterson N, et al. MEGAS: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011;28:2731–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Reyna EA, Aroca MC, Castillo AR, et al. Diffuse cutaneous leishmaniasis: the first report of a parasitologically confirmed case in Ecuador. In: Hashiguchi Y, editor. Studies on New World leishmaniasis and its transmission, with particular reference to Ecuador, vol. 4. Kochi, Japan: Res Rep Ser; 1994. p. 85–92.Google Scholar
- Calvopina M, Gomez EAL, Sindermann H, et al. Relapse of New World diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after Miltefosine treatment. Am J Trop Med Hyg. 2006;75:1074–7.PubMedGoogle Scholar
- Lazo RFS, Hashiguchi Y. Generalized cutaneous leishmaniasis: a parasitologically confirmed case in Ecuador. In: Hashiguchi Y, editor. Studies on New World leishmaniasis and its transmission with particular reference to Ecuador, vol. 4. Kochi, Japan: Res Rep Ser; 1994. p. 93–8.Google Scholar
- Furuya M, Akimaru Y, Mimori T, et al. Identification of species of Ecuadorian Leishmania isolates by ELISA using monoclonal antibodies. In: Hashiguchi Y, editor. Studies on New World leishmaniasis and its transmission, with particular reference to Ecuador, vol. 5. Kochi, Japan: Res Rep Ser; 1997. p. 11–20.Google Scholar
- Hashiguchi Y, Gomez EAL. A review of leishmaniasis in Ecuador. Bull Pan Am Health Org. 1991;25:64–76.Google Scholar
- Calvopina M, Armijos RX, Hashiguchi Y. Epidemiology of leishmaniasis in Ecuador: current status of knowledge—a review. Mem Inst Oswaldo Cruz. 2004;99:1–10.View ArticleGoogle Scholar
- Gomez EAL, Kato H, Hashiguchi Y. Man-biting sand fly species and natural infection with the Leishmania promastigote in leishmaniasis- endemic areas in Ecuador. Act Trop. 2014;140:41–9.View ArticleGoogle Scholar
- Develoux M, Diallo S, Dieng Y, et al. Diffuse cutaneous leishmaniasis due to Leishmania major in Senegal. Trans Roy Soc Trop Med Hyg. 1996;90:396–7.View ArticlePubMedGoogle Scholar
- Azeredo-Coutinho RBG, Conceicao-Silva F, Schubach A, et al. First report of diffuse cutaneous leishmaniasis and Leishmania amazonensis infection in Rio de Janeiro State, Brazil. Trans Roy Soc Trop Med Hyg. 2007;101:735–7.View ArticlePubMedGoogle Scholar
- Kungu A, Mutinga MJ, Ngoka JM. Cutaneous leishmaniasis in Kenya. East Afr Med J. 1972;48:458–65.Google Scholar
- Niamba P, Goumbri-Lompo O, Traoré A, et al. Diffuse cutaneous leishmaniasis in an HIV-positive patient in western Africa. Austral J Dermatol. 2007;48:32–4.View ArticleGoogle Scholar
- Grimaldi Jr G, Tesh RB, McMahoon-Pratt D. A review of the geographical distribution and epidemiology of leishmaniasis in the New World. Am J Trop Med Hyg. 1989;41:687–725.PubMedGoogle Scholar
- Bryceson ADM. Diffuse cutaneous leishmaniasis in Ethiopia. III. Immunological studies. Trans Roy Soc Trop Med Hyg. 1970;64:387–93.Google Scholar
- Walton BC, Velasco O. Leishmaniasis. The distribution and aetiology of diffuse cutaneous leishmaniasis in the New World. NATO ASI Ser. 1989;171:149–57.Google Scholar
- World Health Organization. Control of the leishmaniasis: report of a WHO Expert Committee. Tech Rep Ser. 1990;793:1–158.Google Scholar
- Convit J, Ulrich CT, Fernandez FJ, et al. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans Roy Soc Trop Med Hyg. 1993;87:444–8.View ArticlePubMedGoogle Scholar
- Lainson R. The American leishmaniases. Some observations on their ecology and epidemiology. Trans Roy Soc Trop Med Hyg. 1983;77:569–96.View ArticlePubMedGoogle Scholar
- Couppie P, Clyti E, Sainte-Marie D, Dedet JP, et al. Disseminated cutaneous leishmaniasis due to Leishmania guyanensis: case of a patient with 425 lesions. Am J Trop Med Hyg. 2004;71:558–60.PubMedGoogle Scholar
- Sousa AQ, Pompeu MML, Sólon FRN, Frutuoso MS, et al. Disseminated cutaneous leishmaniasis: a patient with 749 lesions. Braz J Infect Dis. 2006;10:230–0.
- Silveira FT, Lainson R, Corbett CEP. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil—a review. Mem Inst Oswaldo Cruz, Rio de Janeiro. 2004;99:239–51.View ArticleGoogle Scholar
- Mondolfi AEP, Duffey GB, Horton LE, et al. Intermediate/borderline disseminated cutaneous leishmaniasis. Int J Dermatal. 2013;52:446–55.View ArticleGoogle Scholar
- Queiroz A, Sousa R, Heine C, et al. Association between an emerging disseminated form of leishmaniasis and Leishmania (Viannia) braziliensis strain polymorphisms. J Clin Microbiol. 2012;50:4028–34.View ArticlePubMedPubMed CentralGoogle Scholar
- Newlove T, Robinson M, Meehan SA, et al. Old World cutaneous leishmaniasis. Dermatol Online J. 2012;18(12):32.PubMedGoogle Scholar
- Romero HD, Almeida-Silva L, Silva-Vergara ML, et al. Comparative study of serologic tests for the diagnosis of asymptomatic visceral leishmaniasis in an endemic area. Am J Trop Med Hyg. 2009;81:27–33.PubMedGoogle Scholar
- Molinet FJ, Ampuero JS, Costa RD, et al. Specificity of the rapid rK39 antigen-based immunochromatographic test Kalazar Detect(r) in patients with cutaneous leishmaniasis in Brazil. Mem Inst Oswardo Cruz 2013. 108(3). doi:10.1590/S0074-02762013000300006.
- Maia Z, Lírio M, Mistro S, et al. Comparative study of rK39 Leishmania antigen for serodiagnosis of visceral leishmaniasis: systematic review with meta-analysis. PLoS Negl Trop Dis. 2012;6:e1484. doi:10.1371/journal.pntd.0001484. Epub 2012 Jan 31.View ArticlePubMedPubMed CentralGoogle Scholar